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 Background: With the advent of newer and safer  fluids there have been numerous trials 
and studies conducted to test the safety and validity of colloids. Are colloids more effective then 
crystalloid for emergent resuscitation? The purpose of this systematic literature review is to 
assess the claims on treatment success and explore safety to gain clarity on which fluid is the 
best treatment for the patient.  
 Methods:  A systematic database search was conducted from 2006 to the present. The 
search utilized such sources as PubMed, UpToDate and ScienceDirect. This search included 
more than 70 journal articles, where 24 articles were selected for review for their credibility and 
usage within the medical community.  
 Results: Considering the reviewed articles, it seems that the benefits may not outweigh 
the risks inherent with colloids. In summary, using colloids as an alternative to crystalloids made 
little to no difference in the cause of mortality. However, there was evidence that colloids can 
increase the need for renal therapies overall.  
Conclusion: Colloids were merely marginal, if at all, more effective than crystalloids in 
reducing the mortality rates, but with the added risk of renal dysfunction. There are instances 
where colloids might be selected, but those occurrences should be critically challenged. In the 
end, it appears to be left up to clinical judgement, provider experience, and accessibility on 
which fluid selection is optimal.  
 
 





Acute care settings are designed to treat the critically ill and injured. Providers in these 
settings rely on IV fluids for resuscitation of critically ill or injured patients. The goal of this 
paper is to evaluate the effectiveness of IV fluids to determine if colloids are more effective than 
crystalloids in the resuscitation of critically ill adults. The different fluids will be evaluated in the 
setting of sepsis, acute fluid resuscitation in the ICU, hypovolemia, to include hemorrhagic 
shock, and burns patients. The outcome measures will be mortality of these critically ill patients. 
Hemorrhage is responsible for 30 40% of trauma mortality with 33 56% of these deaths 
occurring during the prehospital period.1 Patients that do reach critical care in time to receive 
treatment, mortality can be caused by continued hemorrhage, shock, sepsis, coagulopathy, and/or 
incomplete resuscitation. Altogether, the need for early resuscitation methods is critical. 
Treatment with blood products may not always be available or the right course of treatment for 
patients. Ensuring providers have all the necessary information when making treatment decisions 
is essential, and the reviewed trials provide insight on optimal care. Individual patient profiles 
were examined to determine the effectiveness of colloids.  The discussion of what fluid is most 
suited for patient treatment has been controversial considering the main goal of IV fluids is to 
expand intravascular space. The main discussion that is occurring within the medical community 
is what is the safety and efficacy of fluids in resuscitation. Thus, comparing the long-term patient 
outcomes is essential in determining treatment plans. The fluids that are considered colloids are 
albumin, h dro eth l starch and gelatin. Lactated Ringer s and normal saline (sodium chloride) 
are considered crystalloids. These colloid and crystalloid fluids were given in the reviewed trials. 
 
 




Function of Colloids and Crystalloids 
 Crystalloids have several different compositions and can respond differently within the 
body based on its biochemical structure. Crystalloids that contain sodium and chloride are water-
soluble electrolytes and lack proteins that make the molecules insoluble within the body. 
Crystalloids containing sodium and chloride can be isotonic meaning the fluid can contain the 
same balance and number of electrolytes as the plasma, hypertonic meaning the fluid contains 
more electrolytes than the plasma, or hypotonic meaning the fluid contains less electrolytes than 
the plasma.  Other compositions such as Ringer s lactate contain sodium chloride, along with 
sodium lactate, potassium chloride and calcium. Due to Ringer s lactate cr stalloids having 
additional elemental components, Ringer s lactate cr stalloids are used to replace the fluid and 
electrolytes with a patient that requires extra electrolyte composition. It should be noted, the 
most common isotonic fluids do not cause water to shift between the extracellular fluid and the 
intracellular fluid.2 A major disadvantage of crystalloids is the limited time the fluid remains 
within the plasma. For example, when a patient is treated with a 1000mL bag of fluid, generally 
up to 200 mL of that fluid is maintained within the vascular system and the rest is shifted into the 
interstitial space.2  
 In contrast, colloids contain larger insoluble molecules than those of the crystalloid 
compositions, which can include proteins, complex polysaccharides, albumins, starches, and 
dextran. The larger molecules in colloids will not easily cross the capillary walls and remain 
within the intravascular space for a much longer period than crystalloids, which is where the 
benefit of colloid fluids are supposed to be derived.2 The theory is larger molecules in colloids 
provide the ability to maintain a higher osmotic pressure for longer periods and are publicized as 
the main purpose of colloid fluids.  




 HES is a colloid composed of three hydroxy ethylated starches dispersed into a solution 
of water and salts. HES has two main different compositions HES 200/0.5 and HES 130/0.4, the 
first number represents the molecular weight and the second the ratio of substitution. The 
metabolism of HES is through endogenous amylase, which will break down the starch molecules 
(Figure 1). Next, the broken-down starch molecules will be filtered within the glomerulus and 
excreted into the urine. Considering the substitution ratio of the fluid being applied is extremely 
important. The substitution ratio is the determination of how slow or fast the molecules will 
degrade within the vascular system. The higher the substitution ratio is the longer the molecules 
will remain in the bloodstream, which in turn should require less fluids needing to be given to 
patients over the time of resuscitation. The usage of colloids has been tested in patients suffering 
from sepsis and will be discussed. 
Colloid Usage in Sepsis 
Despite more than 20 ears of intense therapeutic investigation, mortalit  from septic 
shock has remained at approximately 40-50%. 1 Utilizing fluid resuscitation is a mainstay in the 
management of severe sepsis and septic shock. Inadequate initial treatment and dela ed 
hemodynamic stabilization may be associated with increased risk of death in patients with severe 
sepsis. 3 Overall early fluid resuscitation is a major step in the management of severe sepsis and 
leads to improved prognosis. Optimi ed management in the first 6 hours has been reported to 
significantly reduce mortality in patients with severe sepsis and septic shock. 3 Choosing the 
right fluid might be the deciding factor to shift the balance in the patient's favor. Providers must 
weigh the risk and benefits of all the fluids, including risks of acute kidney injury, increased 
bleeding, and allergic reaction/anaphylaxis. The main question that needs to be answered is what 
fluid is best in the treatment of sepsis and septic shock? This is a question that has been 




researched over several clinical trials over the past few years. The reviewed studies provide 
insight into patient management and assist providers in selecting the proper fluid given the 
patient profile. Relevant studies involving sepsis and fluid management examined below as part 
of the overall review.  
Assessment of Hemodynamic efficacy and safety of 6% Hydroxyethyl starch 130/0.4 vs. 
0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study was double-
blind, randomized, controlled multicenter study conducted throughout 24 different medical 
centers in France and three medical centers within Germany. One hundred patients were 
randomized to be treated with Hydroxyethyl starch (HES) and 96 patients were randomized to a 
control group with NaCl. When selecting patients, the origin of sepsis was noted and can be 
found within Table 1. Most patients selected had a prevalence of sepsis within the lungs and 
abdomen. There were no significant differences between treatment groups in demographic and 
baseline characteristics. 4 The Simplified Acute Physiology Score II was used to evaluate 
patients estimated mortality within the ICU. The authors found that there was no significant 
difference in vital signs or hemodynamics within the two study groups. Patients within the study 
received a maximum of 50 ml/kg/day on the first day and 25 ml/kg/day from the second to the 
fourth day. The same formulary was used within both the HES and NaCl groups. It was noted 
that if any fluid was required beyond the four-day time it was intravenous crystalloids with no 
upper volume limit. Patients were followed for a total of 28 days and monitored for all-cause 
mortality. To control for provider bias, the fluids were identical in appearance and packaging. 
The study adequately controlled for biases and ensured the most thorough evaluation of fluids 
was conducted. The study used well established protocols and was found to meet safety 
standards by the French Independent Ethics Committee. 




 The authors found in order to reach the desired hemodynamic stability significantly less 
HES was used than NaCl (1,379 ± 886 ml in the HES group and 1,709 ± 1,164 ml in the NaCl 
group [Mean difference = -331 ± 1,033, 95% CI -640 to -21], P = 0.0185).4 The time to reach 
hemodynamic stability was an average of 2.5 hours shorter within the HES group, however these 
findings were not found to be statistically significant (Table 2). The usage of HES during this 
study did not induce AKI and the tubular or glomerular function was not affected (Table 3). 
Urinar  biomarkers of AKI were used as a ratio to urinar  creatinine. The stud  concluded that 
there was no statistically significant effect on mortality when comparing HES and NaCl 
treatment groups. 4 Therefore, the study found no major differences in mortality when 
contrasting HES to NaCl.  
 In short, this study was one of two trials reviewed that found no major difference between 
the need for renal replacement therapy when using HES over crystalloid for emergent 
resuscitation. This is the only trial that found no difference between the need for renal 
replacement with HES over crystalloid in sepsis. However, this has not been confirmed in larger 
trials. In fact, the opposite was found in larger trials and HES and other colloids should not be 
used within septic patients.  
The next study evaluated is the Scandinavian Starch for Severe Sepsis / Septic Shock (6S) 
trial, which was a large study conducted in 2009- 2022 throughout Denmark, Norway, Finland, 
and Iceland. The trial was a blinded, parallel group with randomized patients (Table 4). A total 
of 1211 patients were evaluated with 407 being excluded for the following reasons: 138 
underwent renal-replacement therapy, 152 received >1000 ml of synthetic colloids, 51 consent 
could not be obtained and 25 were already in another ICU trial. Consequently, 804 total patients 
underwent randomization, where another 4 were excluded from the trial.5 Nonetheless, 400 were 




assigned to receive HES 130/0.42 and 400 were assigned to receive Ringer s Lactate. The trial 
patients all fit criteria for severe sepsis according to the Society of Critical Care Medicine and 
American College of Chest Ph sicians. The composite outcome measure of 90-day mortality or 
end-stage kidney disease defined as dialysis-dependency 90 days after randomization will be the 
primary outcome measure, and these two outcome measures will also be anal ed separatel . 5 
Patients were followed up with at 6 month and 1 -year re-evaluation periods to assess for all-
cause mortality. The need for renal replacement therapy was followed for 90 days after 
randomi ation. The fluids were visuall  identical and were given in 500 ml fle  bag  plastic 
bottles, which were put into black plastic bags to control for provider bias.  
 The primar  outcome, death or dependence on dial sis at 90 da s after randomi ation, 
occurred in 202 patients (51%) in the starch group as compared with 173 patients (43%) in the 
Ringer s acetate group (relative risk, 1.17; 95% CI, 1.01 to 1.36; P = 0.03). 5 The P-value is 
statistically significant and leads the researchers to conclude that patients with severe sepsis 
receiving fluid resuscitation with HES had a higher risk of death at 90 days (Table 5). The 
evaluated probability of survival using Kaplan-Meier analysis, which is a statistical tool that 
measures the fraction of patients living after treatment, showed the survival time did not 
significantly differ between the two groups (P=.07)(Figure 2). The patients within the colloid 
group were more likely to have a need for renal-replacement therapy. The study found that 87 
patients treated with HES required renal-replacement therapy, while only 65 patients treated with 
Ringer s Acetate required renal-replacement therapy (relative risk, 1.35, 95% CI, 1.01-1.80; 
P=.04. In short, this shows a statistically significant value when evaluating the relative risk. 
Incidences of acute kidney injuries were found to have more than three points within the 
Sequential Organ Failure Assessment score (SOFA), which means the patients would have a 




higher need for dialysis. The need for renal-replacement therapy, lengthens the time a patient 
will require to stay within a healthcare facility; defined within the article as days alive outside of 
the medical facility (Table 5). The mean days alive outside of the hospital was 29 with HES and 
34 with Ringer s Acetate, which also increases a patient's risk profile. Patients being hospitalized 
for a longer time can increase their mortality risk, due to iatrogenic causes. Within this study it 
was found that less overall fluid would be required for a patient to return to hemodynamic 
stability. The issues lie with the risk of using colloid fluids within the environment of severe 
sepsis. Consequently, the data in the clinical trial argues that patients with severe sepsis should 
not be treated with HES due to the increased mortality risk and dependency of renal replacement.  
Colloid Usage in Treatment in Intensive Care Patients 
The usage of intravenous fluids to increase intravascular volume is essential in treatment 
of patients within intensive care units and emergency departments in saving lives around the 
world. Globally, 0.9% sodium chloride (saline) is the most used fluid, although colloids were 
administered almost as often as crystalloids with intensive care patients. HES is the most 
frequently used colloid. Initially, colloid usage showed promise since colloids can safely and 
efficiently provide fluid resuscitation. However, there is an increased risk of kidney injury when 
using colloids. 
Hydroxyethyl Starch for Fluid Resuscitation in Intensive Care (Chest) is a clinical trial 
that was conducted from December 2009 through January 2012. The authors released a paper on 
statistical analysis.6 Similarly, this trial was modeled after the Saline versus Albumin Fluid 
Evaluation (SAFE) trial. The primary outcome was assessed from a standardized X2 test 
demonstrating the statistical significance of the treatment and monitored for 90-day all-cause 
mortality. Cox proportional hazard model was utilized to obtain P-values and hazard ratio and 




was conducted by blinding the study-groups assignments within medical-surgical ICUs in 
Australia and New Zealand. 7000 patients were enrolled through 32 different medical centers. 
3500 patients were to receive 6% HES and 3500 were to receive 0.9% normal saline. The patient 
eligibility can be seen in Table 6 in the appendix. Indistinguishable Free flex 500-ml bags were 
used, which assisted in the blinding ensuring to reduce the provider bias. The study used a 
ma imum of 50 ml per kilogram dosage of 6% HES (130/0.4). Independent anal sis of the 
concentration and degree of molar substitution of HES and the concentration of saline was 
obtained for a random sample of 20 bags with the use of gravimetric analysis and nuclear 
magnetic resonance spectroscop  (Chemical Anal sis). 6 The analysis of fluids allowed the 
authors to ensure the fluids were properly prepared and uniform for use within the trial. 
Controlling for the fluids was essential to ensure the removal of any additional variables from the 
trial. Such as different fluid levels within the stud  fluids. Stud  treatments were randoml  
assigned over an encrypted Web-based randomization system with the use of a minimization 
algorithm stratified according to institution and an admission diagnosis of trauma. 6 If the 
patients required more than the prescribed fluid amount, within the first 24-hour period, the 
patients would be given 0.9% normal saline. All other aspects of care for the patients were 
conducted at the discretion of the treating clinicians.  
In the HES group, 597 of 3315 patients (18.0%) died within 90 da s after 
randomization, as compared with 566 of 3336 patients (17.0%) in the saline group (relative risk 
in the HES group, 1.06; 95% confidence interval [CI], 0.96 to 1.18; P = 0.26). 6 Therefore, there 
was no significant difference in the primary outcomes of the study and there is no difference with 
90-day mortality when comparing HES to normal saline. Despite the lack of difference in 
survivability between HES and normal saline is a surprising result that has been replicated in 




subsequent trials. Even in the situation that HES was developed for, it did not have any effect on 
overall survival. In conclusion, our study does not provide evidence that resuscitation with 6% 
HES (130/0.4), as compared with saline, in the ICU provides an  clinical benefit to the patient. 6 
Once again, the issue with utilizing HES comes from the risk of acute kidney injuries to 
the patients. Renal-replacement therapy was administered to 235 of 3352 patients (7.0%) in the 
HES group and 196 of 3375 patients (5.8%) in the saline group (relative risk, 1.21; 95% CI, 1.00 
to 1.45; P = 0.04). 6 Analysis was conducted to show that serum creatinine levels were 
significantly increased within the HES groups. This increase in creatinine was seen initially and 
grew exponentially over day one to three (Figure 3), while the urine output was slightly 
decreased (Figure 4). The relative risk of the creatinine and urine-output components were 
analyzed using RIFLE criteria. Both met criteria for kidney dysfunction (RIFLE-R) or within the 
kidney injury (RIFLE-I). The use of HES led to an overall increased need for renal-replacement 
therapy and was found to be statistically significant.  
Additionally, the study noted an increased need for blood products with the patients 
treated with HES and patients had a decreased rate of new cardiovascular failure. The Sequential 
Organ Failure Assessment (SOFA) score was used to analyze results, which demonstrated a 
reduced need for vasopressors in patients that were treated with HES. The decreased need for 
vasopressors was attributed to the increased intravascular expansion of HES fluid resuscitation. 
However, patients treated with HES showed an increase of treatment-related adverse events, 
such as pruritus and skin rash. The adverse skin events occurred at a rate of 1.8 times higher 
within the HES subgroups, with 169 patients having one of these adverse events. The normal 
saline group only had adverse skin events occur within 87 patients. The findings of adverse skin 
events are significant statistical findings with a P value of .006 (Figure 5). A possible cause of 




increased adverse skin events with HES groups could be caused by an accumulation in tissue, 
specifically the reticuloendothelial system, which is manifested by pruritus with the potential of 
leading to AKI and hepatic injuries. 
In contrast to HES, the study A Comparison of Albumin and Saline for Fluid 
Resuscitation in the Intensive Care Unit (SAFE) compared albumin to saline. The primary 
outcome of trials was all-cause mortality at 28 days after inclusion into the trial. Also noting if 
patients had any new organ failure. The study was double blinded, randomized and conducted 
from 2001 to 2003 in 16 intensive care units across Australia and New Zealand. SOFA scores at 
baseline were utilized and any higher scores were reported every day for seven days, followed by 
tests every third day until discharged from the ICU or until the 28-day marker was reached. 
Importantly, the need for mechanical ventilation, need of renal-replacement therapy, and length 
of ICUs admissions were additionally noted.6 Of the 6997 patients selected for the trial, 3497 
were assigned to receive albumin and 3500 to receive normal saline. Exclusion criteria for the 
study included patients that underwent cardiac surgery, liver transplants and those undergoing 
treatment for burns.6 The exact breakdown of patient characteristics upon admission into the 
clinical trial can be seen in Table 7 in the appendix. Dissemination within the study consisted of 
the colloid group receiving four percent albumin and crystalloid group receiving normal saline. 
The study was blinded and used identical masked cartons, however, the fluid amount and rates 
were determined by the treating providers and not chosen by the study investigators. The study 
investigators utilized George Institute for International Health at the University of Sydney, a 
secondary independent agency to assess the data analysis and manage the data collected.  
When comparing the primary outcomes, there were 726 deaths in the albumin group and 
729 in the saline group. (relative risk, 0.99; 95% CI, .097 to 1.09; P = 0.87).6 When assessing for 




new organ failure using the SOFA scores there was no significant difference. A Fischer s e act 
test was utilized to reach a P-value of 0.85. The need for renal-replacement therapy was 
statistically non-significant (relative risk, 0.09; 95% CI, 0.0 to .19; P = 0.41), meaning there was 
no difference in the need for renal-replacement therapy between the two groups.  
Conversely, the results from this clinical trial refute findings from a previous clinical 
trial, Crystalloids vs. colloids in fluid resuscitation: a systematic review and was conducted in 
1999, which reports patients that were treated with albumin in the ICU had a higher all-cause 
mortality.6 Conversely, the results from this clinical trial refute findings from a previous clinical 
trial that reports patients that were treated with albumin in the ICU had a higher all-cause 
mortality. This previous study was Crystalloids vs. colloids in fluid resuscitation: a systematic 
review and was conducted in 1999.6 Additionally, the results refute the evidence put forth by the 
Cochrane Injuries Group Albumin Reviewers  meta-analysis, which suggested that there would 
be an increase in mortality if patients were treated with albumin during resuscitation.15 However, 
the trial did show evidence in patients that were suffering sepsis having a lower all-cause 
mortality when treated with albumin, but this was not a specific outcome within the study (Table 
7). Nonetheless, the results showing lower all-cause mortality with albumin treatment could be a 
result of chance, so further studies into the specifics would be needed to confirm outcome 
causation. 
Colloid Usage in Hypovolemia 
Hemorrhage accounts for up to 40% of trauma-related deaths.7 Restoring end-organ 
perfusion and tissue oxygenation must be attained within a short time to reduce mortality. Most 
of the mortality occurs within 6 hours after injury and this critical time is where selecting the 
right fluid becomes essential.7 Colloid usage within hypovolemic patients has not been nearly as 




controversial. Colloids are regularly utilized within the United States and abroad for volume 
resuscitation. 
Effects of fluid resuscitation with colloids vs. crystalloids on mortality in critically ill 
patients presenting with hypovolemic shock (CRISTAL), was a study conducted in February 
2003 to August of 2012. Patients were selected from 57 different ICUs in France, Belgium, 
Canada, Algeria, and Tunisia. Initially, 6498 patients were assessed for eligibility, while only 
2857 were selected due to exclusion criteria. Patients were randomized into a colloid group and a 
crystalloid group, 1414 to colloids and 1443 into crystalloid groups, respectively.8 To be 
included in the CRISTAL study the patient must meet the following criteria for hypovolemia.  
require fluid resuscitation for acute h povolemia as defined b  the combination 
of (1) hypotension: systolic arterial pressure of less than 90 mm Hg, mean arterial 
pressure of less than 60 mm HG, orthostatic hypotension (i.e., a decrease in systolic 
arterial pressure of at least 20 mm Hg form the supine to the semi recumbent position), or 
a delta pulse pressure of 13% or higher; (2) evidence for low filling pressures and low 
cardiac index as assessed either invasively or noninvasively; and (3) signs of tissue 
hypoperfusion or hypoxia, including at least 2 of the following clinical symptoms: a 
Glasgow Coma score of less than 12, mottled skin, urinary output of less than 25 mL/h or 
capillary refilling time of 3 seconds or longer; and arterial lactate levels higher than 2 
mmol/L, blood urea nitrogen higher than 56 mg/dL, or a fraction excretion of sodium of 
less than 1%.8   
The patients were not supposed to receive any fluids prior to admission into the clinical 
trial, most patients excluded were due to receiving fluids prior to admission. The other exclusion 
criteria encompassed anesthesia related hypotension, chronic liver disease, chronic renal failure, 




or acute anaphylactic reaction.8 A computer-generalized list was utilized with a fixed-block 
permutation, which randomized patients into a 1 to 1 ratio. The crystalloid group could use any 
hypertonic saline, isotonic solution, and buffered solutions.  
The study allowed for usage of several different colloids, to include hypo-oncontics such 
as gelatins and albumins and hyperoncotics such as dextrans, hydroxyethyl starch and 20% or 
25% albumins. The different treatment groups could select whatever fluid that was available 
within the facilities with the only restriction set within the colloid group to limit the dosage of 
hydroxyethyl starch to no more than 30ml/kg of body weight. Moreover, the providers were 
required to follow any local regulations set for usage of these fluids. Unlike previous studies 
discussed above, the study advisors did not deem it possible to blind the clinicians to the fluid 
interventions. Due to the interventions lasting throughout a patient s time within the ICU, it 
would not be possible to provide enough masked fluids solutions for adequate resuscitation and 
completion of the study. Instead, the investigators, sponsors, and members of the monitoring 
board were blinded when statistical analysis was conducted. The primary outcomes of this study 
were mortality at 28-days.  
Importantly, the median fluid administered for the first week was 2000 mL of fluids with 
the patients in the colloid group and 3000 mL of fluids in the crystalloid group. When assessing 
the primary outcome of mortality at 28-days, the study concluded that there was no significant 
difference. There were 359 deaths in the colloid group and 390 deaths within the crystalloids 
group (RR, 0.96 [95% CI, 0.88-1.04], P=0.26).1 Surprisingly, this study showed there was no 
difference in the need for renal replacement therapy when comparing the two different types of 
fluids of colloids and crystalloids.  




During the study there were 156 patients in the colloid group and 181 patients in the 
crystalloid group that identified a need for renal replacement, which was not found to be 
statistically significant.8 The discrepancy in renal replacement needed compared to other studies 
could be due to other studies focused more on HES than multiple different colloids and the fact 
that the dosage of starches never exceeded the dose recommended by regulatory agencies.8 Be 
that as it may, there was a significant difference in the mortality at 90-days for colloids vs 
crystalloids, showing 434 deaths in the colloid groups and 493 deaths in the crystalloid 
groups(RR 0.92 [95% CI,0.86 -0.99], P=.03).8 Conversely, there was a significant difference in 
mortality noted within the colloid and crystalloid study groups, which need further exploration to 
reach a conclusion of efficacy. Furthermore, resuscitation with colloids can be associated with 
faster removal of life-support, which was exhibited by the mean number of days being alive 
without mechanical ventilation within the colloid group being significantly lower. (Mean 
difference, 1.10 [95% CI, 0.14-2.06], P=0.01). The results from this clinical study were limited, 
due to the study outcomes and short timeframe of patients being tracked. Consequently, a 
statistically significant difference was found between the average base excess serum after fluid 
therapy (Figure 6) with a P-value of .001.8  
Comparison of the Effectiveness of Hydroxyethyl Starch (Voluven) Solution With Normal 
Saline in Hemorrhagic Shock Treatment in Trauma (VOLUVEN Trial) was conducted in 2016 at 
Imam Khomeini Hospital in Ahvaz, Iran consisting of 100 initial participants. A total of 12 
patients were excluded due to death, blood transfusion, or transference to an operating room. The 
colloid group received .5 L of colloid solution with 1.5 L of normal saline and the crystalloid 
group received 2 L of normal saline. This stud s approach was unique in the fact that the stud  
utilized a calculation of base excess status when comparing crystalloid vs colloids. The primary 




outcome of the clinical trial was established by measuring the base excesses before and after 
fluid therapy by drawing of ABG samples, 1 hour after administration.9 Outcomes were 
calculated by utilizing covariance analysis and linear methods.9 This stud s approach was 
unique in the fact that the study utilized a calculation of base excess status when comparing 
crystalloid vs colloids. The primary outcome of the clinical trial was established by measuring 
the base excesses before and after fluid therapy by drawing of ABG samples, 1 hour after 
administration.9 Outcomes were calculated by utilizing covariance analysis and linear methods.9 
Colloid Usage in Burn Resuscitation 
To treat burns in an acute setting requires a large amount of fluid resuscitation. Fluid 
resuscitation in burn patients is essential to effectively reduce mortality and lead to improved 
outcomes. The inflammatory response that occurs during burns can surpass that seen with trauma 
and sepsis patients.10 Large fluid shifts that occur in severely burned patients with delaying, or 
inadequate resuscitation can cause hypovolemia, tissue hypoperfusion, shock and organ failure. 
Currently the fluid of choice for resuscitation is Lactated Ringers. The current Parkland 
formulary can underestimate the actual fluid required for resuscitation.10 However, the Parkland 
formula excludes the usage of colloids within the first 24 hours of fluid resuscitation. The initial 
assumption is if colloids were used within fluid resuscitation the colloid would leak across 
capillaries and exert osmotic pull, which could draw more fluid into the interstitial spacing.  
Nevertheless, the fear of colloid leakage is unsubstantiated and is reviewed in Comparison of the 
Effectiveness of Hydroxyethyl Starch (Voluven) Solution With Normal Saline in Hemorrhagic 
Shock Treatment in Trauma. The increase in fluid resuscitation can correlate with an increased 
intra-abdominal pressure and abdominal compartment syndrome. Colloid usage has shown to 
help limit the overall volume needed to reach hemodynamic stability and reviewed in 




Hydroxyethyl starch supplementation in burn resuscitation—A prospective randomized 
controlled trial. 
The clinical trial Hydroxyethyl starch supplementation in burn resuscitation—A 
prospective randomized controlled trial was conducted May 2004 to May 2006 at University 
Hospital Birmingham Burns Centre in the United Kingdom. Patient inclusion criteria constituted 
having burns exceeding 15% of total body surface area (TBSA) excluding those that had a 80% 
TBSA, were pregnant, or had a delay of transfer greater than 6 hours from the time of injury.11 
The Lund & Browder chart was employed for estimation of body surface area burned, this was 
confirmed by two members of the staff.11 A block randomization was chosen to distribute the 
patient allocation incoherently in the trial. The study began with 43 patients and only concluded 
with 26 patients that completed the fluid trial and used for data analysis. The crystalloid group 
was given Hartmann s solution according to the Parkland formula, which is the normal practice 
for local hospitals. Meanwhile, patients selected for the colloid group received two-thirds 
resuscitation of Hartmann s solution and one-third of the fluid replaced with 6% HES, with max 
dosing of HES of 33ml/kg for 24 hours. However, the maximum dose given would not allow for 
the full one-third to be replaced with HES. Instead the maximum allowed volume of HES was 
infused at a regular rate and halved at 8 hours post-injury.11 The e pansive value of 6% HES is 
in the region of 1:1.5, which means the blood volume expansion is achieved is 1.5 times the 
volume of HES infused. The total 6% HES hourly volume allowance was translated into its 
crystalloid equivalent, by multiplying it by 1.5. The resulting volume was subtracted from the 
predicted crystalloid requirement for the hour which provided the hourl  Hartmann s volume to 
be infused. 11 Fluid resuscitation was titrated by the following criteria: Urine output of .5-
1ml/kg/h in uncomplicated burns and 1-2 ml/kg/h in inhalation injury with mean arterial pressure 




>70 mm HG and heart rate <120bpm.11 The tracking of Albumin-creatinine ratio (ACR) was 
used to indicate endothelial dysfunction between the two groups and was used to determine the 
primary outcome for the clinical trial. ACR was utilized as a marker for capillary leakage and 
overall edema within the patients. Out of the 43 originally selected patients 26 were allowed into 
the trial (Table 10). The mean TBSA for the study was 27%.  
The primary outcome was concluded that in supplementation of HES in burn patients, 
HES allowed for smaller fluid volume requirement (Table 10) and less tissue edema within the 
first 24 hours (Table 11). The fluid requirement was corrected for the TBSA of each patient 
suffering burns. The results of lower median serum CRP at 48 hours is statistically significant 
with a P-value of .0001 within the treatment group of colloids. The ACR measurement at 12 
hours when factoring in TBSA with a P-value of .0310 was found to be significant, within the 
treatment group of colloids. This reduction in serum CRP allowed the investigators to draw the 
conclusion that with treatment addition of colloids to burn regiments, patients with burns can 
benefit from treatment within the first 24 hours.11 Withal, none of the patients within the clinical 
trial required renal-replacement therapy, which can be related to the reduced dosage of HES that 
was highlighted above.  
A Prospective, Randomized Evaluation of Intra-abdominal Pressures with Crystalloid 
and Colloid Resuscitation in Burn Patients was conducted at burns center in California and 
Pennsylvania in 2002 and published in 2005. To meet inclusion criteria, patients had to have at 
least 25% TBSA with smoke inhalations or greater than 40% TBSA if no inhalation injury was 
present. Patient randomization was conducted by predetermined order produced in groups of 10. 
Patients assigned in the crystalloid group applied the Parkland formula for volume resuscitation. 
Utili ation of Lactated Ringer s at a rate of 4 mL/ kg/%TBSA, first half over initial 8 hrs.12 




Patients assigned to the colloid group were given plasma and crystalloid combination. The 
patients in the colloid group were initiated on a 24-hour goal of 2,000 mL of Lactated Ringer s 
and 75 mL/kg of fresh frozen plasma (FFP).12 The FFP was titrated to maintain urine output 
between 0.5 and 1.0 mL/kg/h12. The primary outcome was a measure of intra-abdominal pressure 
(IAP) measured in mmHg, which is an indication of the threshold for intra-abdominal 
hypertension.  
Conditions where fluids given were substituted with colloids such as FFP, a reduction 
could be observed in the overall amount of fluids required for resuscitation and reduce the 
overall occurrence of abdominal compartment syndrome with inevitably serious complications. 
There was a statistically significant rise within both groups in measured IAP. The crystalloid 
group had a rise to a mean IAP of 32.5mm Hg, which showed an increase of 26.5 mm Hg.12 The 
colloid group had a rise to a mean IAP of 16.4 mm Hg, which only increased by 10.6 mm Hg.12 
Altogether, the IAP increase of the crystalloid and colloid groups had a statistically significant P-
value of .0001. The patients within the plasma group were given less fluids overall throughout 
study, averaging only .561 L/kg. This clinical trial showed a direct relationship in the amount of 
fluid given to a patient and overall IAP.  
A mere 31 patients reached the end of the trail, creating a major confinement for overall 
data analysis. To fully test these numbers with a power of 80%, with a 10% difference in 
survival, expecting a P-value of .05 would require an inclusion rate of over 900.12 The 
investigator deemed full analysis unattainable, even if utilizing a large multi-institutional study.12 
Without a study of significant magnitude being conducted, the outcomes could not be directly 
confirmed.  
 





PubMed, Science Direct and UpToDate were specifically searched to find articles that 
conducted trials on colloids, and additionally explored articles that conducted trials where 
providers compared colloids to crystalloids directly. The keywords utilized within the search 
were colloid, cr stalloids, emergenc , resuscitation, burns, mortalit , shock, burns and sepsis .  
Search criteria included peer-reviewed articles and clinical trials within the past 16 years. Of the 
70 articles and clinical trials reviewed, 7 clinical trials and 13 articles were selected. These were 
selected for their relevance to the topic, timing of clinical trials conducted and impact on 
regulations for colloid usage. Several of the articles were selected for their direct reference in 
FDA and European guidelines.  
Discussion 
Providers utilizing IV fluids for resuscitation to critically ill patients want to provide the 
treatment with the best possible outcomes. The goal of this paper is to address if colloids usage 
would allow for improved outcomes. Several conclusions can be drawn from the research and 
will be discussed in each of the critically ill settings: including sepsis, hypovolemia, and burns. 
Additionally, the studies reviewed have limitations that are addressed.  
Patients suffering from sepsis or septic shock were reviewed within the CRYSTMAS and 
6S clinical trial. These trials show conclusive evidence against the usage of colloids within 
patients suffering sepsis. Both studies used HES in place of the colloid. The CRYSTMAS study 
chose to utili e normal saline, while the 6S chose to give Lactated Ringer s. This difference in 
crystalloid selection had very little to no impact on the outcomes of the clinical trial. In the 
CRYSTMAS and 6S clinical trial found no difference in mortality in septic patients. However, 




there was a difference in the two trials when comparing the need for renal replacement therapy. 
In the CRYSTMAS trial the investigators found no statistically significant difference in the need 
for renal replacement when comparing colloid vs crystalloids. The 6S clinical trial found a 
statistically significant difference in the need for renal replacement when comparing colloids to 
crystalloids. These differences could be due to the limitation within the CRYSTMAS study. The 
CRYSTMAS study had a small patient population. This limited population size can lead to 
unreliable findings and not provide a full picture when comparing the two fluids. The main 
limitation within the CRYSTMAS study was the overall purpose of the study was not assessing 
the mortality, but focused on which IV fluid would allow a patient to reach hemodynamic 
stability fastest. One factor that could have affected the findings in the 6S clinical trial was the 
inclusion of patients that had AKI prior to application of the fluids. The inclusion of patients 
suffering from AKI could have affected the data and patient need for renal replacement therapy. 
As these patients suffering from AKI already have kidney dysfunction and could have led to the 
increased need for renal replacement therapy. Even with these limitations, there is no difference 
in mortality when treating patients with colloids vs crystalloid. Colloids have the increased risk 
of acute kidney injury in sepsis making the fluid benefit not worth the risk.  
  Hypovolemia and hypovolemic shock were tested within the CRISTAL and the 
VOLUVEN clinical trials. The outcomes of the CRISTAL study were tracking mortality and the 
need for renal replacement.  Within the VOLUVEN clinical trial the outcome was not following 
mortality but calculating the base excess status when comparing crystalloids vs colloids. The 
findings of this clinical trial indicated that colloids are superior to crystalloids if properly 
administered to patients in hypovolemia and hypovolemic shock. This is most apparent in the 




CRISTAL trial where the authors found a significant difference in mortality supporting colloids 
vs crystalloids.  
There was some limitation within both clinical trials. The CRISTAL clinical trial was 
running over a period of 9 years. This is a long time to run a study and could prove difficult to 
maintain consistency in treatment protocols within the medical facilities. There was no mention 
if the trials controlled for these changes. There was no blinding of fluids within either the 
CRISTAL or VOLUVEN trials. These trials noted that it was not feasible to blind the fluids. The 
CRISTAL trial did note a chance of bias, but the authors refuted the claim b  stating, this would 
have likely resulted in an increased use of renal replacement therapy in patients treated with 
colloid. 8 The CRISTAL trial showed no significant difference in the need for renal replacement 
therapy when comparing crystalloid and colloids. Within the VOLUVEN clinical trial there was 
a much smaller patient cohort. Without adequate data points it can lead invalid data overall. The 
authors did not track mortality, but instead collected data on base excess status when comparing 
crystalloids to colloids. Other crucial sepsis indicators such as lactate were not collected. 
Burn treatment with colloids was tested within clinical trials A Prospective, Randomized 
Evaluation of Intra-abdominal Pressures with Crystalloid and Colloid Resuscitation in Burn 
Patients and Hydroxyethyl starch supplementation in burn resuscitation—A prospective 
randomized controlled trial. These clinical trials did show some compelling evidence for the 
usage of colloids within burn patients. There were several limitations within both clinical trials. 
The two clinical trials used completely different colloids. One utilizes FFP and the other used 
HES. This difference in types of colloids used could lead to changes in the results from each 
study. Both clinical trials were hindered by the number of patients within the cohort, which can 
lead to issues with validity in the outcomes of the clinical trials. Additionally, it is almost 




impossible to completely control differences in full thickness burns between the control and 
study group. However, the investigators attempted to control for this by changing the fluid 
calculation and ACR. This was noted to be a valid control but having different thicknesses and 
locations of burns can affect the results.  
Conclusion: 
In emergent resuscitation, efforts in the setting of sepsis, hypovolemia and burns, a 
provider has the options of colloids or crystalloids. This paper evaluated the effectiveness of 
colloids and crystalloid fluids to compare the outcomes of mortality. In the setting of sepsis, 
there is not enough evidence to support the usage of colloids. Several studies conducted show no 
decrease in mortality. This includes the CRYSTMAS and 6S clinical trial that showed no 
decrease in mortality in patients presenting in severe sepsis. The amount of fluid resuscitation 
needed by patients in sepsis is massive. Confirmed by the CRYSTMAS and 6S, the need for 
patients to undergo renal replacement therapy after resuscitation with colloids is a definite risk if 
the patients are in severe sepsis or septic shock. Acceptedly, during the clinical trials reviewed, 
colloid usage should not be used within sepsis and septic shock. There is little debate on 
restricting colloid usage in terms of septic patients. The medical community and guidelines have 
been established within the United States and the European union. These guidelines have 
established treatment protocols that restrict the usage, and these are supported by the findings 
within the CRYSTMAS and 6S clinical trials.  
Importantly, there is evidence to support the usage of colloids within hypovolemia, but 
some restrictions that must be placed on its usage. Several studies have come out to show that 
HES should not be used due to increased risk of AKI (CRYSTMAS and 6S). However, the trials 
were tested in a population with signs of sepsis and septic shock, so should not be considered as 




direct results for treatment of hypovolemia.  Albumin does seem to show promise if utilized 
appropriately with a combination of crystalloid. Demonstrated, the risk of renal-replacement 
therapy can be mitigated with lower doses of HES and colloids. During the larger CRISTAL 
trial, the results illustrated no increased need for renal replacement therapy and showed a 
reduction in all-cause mortality at 90 days. Authors noted an inherent need for more studies to be 
conducted to support finding of reduced renal replacement therapy need and reduction of 
mortality due to not being the direct outcome being tested. Altogether, the large-scale study 
allowed HES or other colloid usage to be recognized for faster patient recovery by manifesting a 
significantly lower mean number of days alive without mechanical ventilation within the colloid 
group. Nonetheless, the results of the clinical trials do not directly support the fear of using HES 
or other colloids in hypovolemic shock. More studies are required with restricted dosages to 
verify if HES does cause a need for renal-replacement therapy. Once additional study has been 
conducted on restricted HES dosages, there is potential for a shift within treatment protocols. As 
it currently stands, most treatment protocols forgo the usage of colloids, specifically HES in any 
circumstances. Even though HES may never become as utilized or as effective as initial claims, 
HES could have a purpose when used in a more restrictive and isolated environment.  
Colloids usage within burns has not been extensively studied in larger multi-institutional 
studies in recent years. There is evidence that colloids can be effective within burn patients in the 
right circumstances. However, several smaller studies show promising results using either HES 
or plasma for substitution in fluid resuscitation. Results demonstrating colloid usage in burns can 
be seen within Hydroxyethyl starch supplementation in burn resuscitation—A prospective 
randomized controlled trial and A Prospective, Randomized Evaluation of Intra-abdominal 
Pressures with Crystalloid and Colloid Resuscitation in Burn Patients. Promise is shown with 




colloid fluids, whether using references of IAP or measures of ACR for endothelial dysfunction. 
The ability for providers to reduce the amount of crystalloid usage by an addition of colloid 
could lessen the impact of resuscitation needed in burn patients. Even so, ensuring providers set 
clear goal directed recitation is essential. Within the article Fluid resuscitation Management in 
patients with burns: update discusses the following:  
Although there are reports of poorer outcomes in septic patients with the use of HES, the 
current scientific evidence does not suffice to support a specific contraindication for HES 
use in burn patients. As was the practice in many burn units, we formerly used HES after 
the first 24 h when it was needed and we did not have the impression that outcomes were 
worse in our patients, but this is a subjective evaluation.13 
Several of the meta-analysis referenced that burn patients should not be given HES. In some of 
the larger studies burn patients were excluded from the studies. Then clinicians use these studies 
that excluded burn patients to draw conclusions that HES should not be given.   
There needs to be a more in-depth clinical trial when utilizing colloids in early burn 
management as the studies Hydroxyethyl starch supplementation in burn resuscitation—A 
prospective randomized controlled trial and A Prospective, Randomized Evaluation of Intra-
abdominal Pressures with Crystalloid and Colloid Resuscitation in Burn Patients show validity 
in colloid usage. The article Fluid resuscitation Management in patients with burns: update 
discusses the following:  
Multicenter randomized controlled trials on fluid resuscitation in major burns are still 
needed to define the best fluid therapy in this population. Data is lacking on the optimal 
end points for TTD, the difference between initial resuscitation with Ringer's lactate or 




Ringer's acetate, the proper timing to initiate colloids, and the comparative performance 
of the different natural and synthetic colloids in burn patients.13  
It has been concluded, healthcare providers should not use HES in patients in sepsis, 
kidney impairment, or in critically ill patients, and restricted use of HES is supported by the 
European Union of the Coordination Group for Mutual Recognition and Decentralized 
procedures- Human- and by the FDA in the United States. However, HES is supplied to EU only 
accredited hospitals for use, but specific training is required for the safe use of HES solutions. 
For safety, specific warnings on the packaging and the top of the product illustrate that HES 
medicines should not be used in patient profiles with sepsis, kidney impairment, or in critically 
ill patients.14 An additional added contraindication included severe coagulopathy, which was not 
discussed within this paper and HES must be discontinued at the first sign of coagulopathy. 
Additionally, HES solutions for infusion are contraindicated in dehydrated patients, 
hyperhydrated patients, patients with intracranial or cerebral hemorrhage, burn injuries, severe 
hyperkalemia, hypernatremia, hyperchloremia, congestive heart failure, organ transplant patients 
and patients with impaired hepatic function.14 However, some of the contraindications are not 
confirmed risks within clinical trials, such as burns.  
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Figure 1. Hydroxyethyl Starch molecule with the action of amylase
Table 




1. Patient Demographics and baseline characteristics for patient in the CRYSTMAS study
 
 
Table 2: Efficacy outcomes during the CRYSTMAS study
 
 




Table 3: Urinary Biomarkers of AKI as a ratio to urinary creatine within the CRYSTMAS Study. 
 
Table 4: Patient selection for 6S clinical trials. 
 






Table 5: Primary and secondary results from the 6S clinical trial
 
 




Figure 2: Kaplan-Meier anal sis for the patient s probabilit  of survival within the 6S clinical trial. 
 
 




Table 6: Patient eligibility for the CHEST clinical trial
 





Figure 3: Serum Creatine in patients during the CHEST clinical trial
 
 
Figure 4: Urine output in patients during the CHEST clinical trial
 




Figure 5: Patient outcomes and adverse events within the CHEST clinical trial
 












Table 8: Paitient enrollment within the CRISTAL clinical trial 
 








Figure 6: Base Excess changes Comparison of the Effectiveness of Hydroxyethyl Starch (Voluven) Solution 
With Normal Saline in Hemorrhagic Shock Treatment in Trauma clinical trial 
 
 
Figure 7: Patient recruitment for burns fluid resuscitation in Hydroexyethylstarch supplementation in 
burn resucitation
 








Table 11: Inflammatory marker data for Hydroxyethylstarch supplemetnation in burn resucitation clinical 
trial  
 
Table 12: Peak results and findings for A Prospective, Randomized Evaluation of Intra-abdominal 
Pressures with Crystalloid and Colloid Resuscitation in Burn Patients 
 

